Cytrellis Biosystems Completes $50 Million Series C Financing
The financing was led by D1 Capital Partners, and proceeds will be utilized to develop the company’s commercial infrastructure as well as support additional clinical research, product development, and manufacturing.
Read More
Cytrellis Announces FDA Clearance For Breakthrough ellacor® Micro-Coring® Technology
Cytrellis announced that the U.S. Food and Drug Administration has cleared their first proprietary product, the ellacor® system with Micro-Coring® technology, for the treatment of moderate to severe wrinkles in the mid to lower face.
Read More
Cytrellis Named A Finalist In Prestigious Innovation Competition
Cytrellis was named a finalist in the prestigious Terra2 Solutions Skin Health Innovation Competition at the Winter Clinical Dermatology Conference Jan 16-24! The competition is for companies developing game-changing technologies for skin health.
Read More
“Women In Aesthetics” Series Is Featuring Karen Cronholm, President And CEO Of Cytrellis.
As seen in Modern Aesthetics
Industry veteran Wendy Lewis sat down with Karen Cronholm to find out what she has learned along her path to CEO of an emerging aesthetics company. They discuss Karen’s start in the aesthetics field, her mentors, advice for the industry’s rising stars and much more.
Read More